Rigel Pharmaceuticals (RIGL) Interest Expenses (2010 - 2026)

Rigel Pharmaceuticals has reported Interest Expenses for 10 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 22.67% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 12.63% YoY), and the FY2025 full-year result was $7.3 million, down 7.55% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.4 million, down from $1.7 million in the prior quarter.
• The five-year high for Interest Expenses was $2.1 million in Q3 2024, with the low at $569000.0 in Q2 2022.
• Average Interest Expenses over 5 years is $1.6 million, with a median of $1.9 million recorded in 2023.
• Year-over-year, Interest Expenses slumped 67.65% in 2022 and surged 227.24% in 2023.
• Tracing RIGL's Interest Expenses over 5 years: stood at $1.1 million in 2022, then soared by 72.27% to $1.9 million in 2023, then advanced by 2.52% to $2.0 million in 2024, then dropped by 13.09% to $1.7 million in 2025, then decreased by 15.66% to $1.4 million in 2026.
• The last three Interest Expenses figures came in at $1.4 million (Q1 2026), $1.7 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison